To include your compound in the COVID-19 Resource Center, submit it here.

Volume of comments delays Foundation coverage decision

After missing the Feb. 28 decision date, the Centers for Medicare & Medicaid Services (CMS) said it will "soon" issue a final National Coverage Determination (NCD) for next-generation sequencing (NGS) cancer diagnostics, including FoundationOne CDx from Foundation Medicine Inc. (NASDAQ:FMI).

FoundationOne

Read the full 408 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE